Proton Therapy Collaboration Leverage Leo Cancer Care's ongoing partnerships with Mevion Medical Systems and Stanford Medicine to explore joint procurement or integration opportunities for upright positioning and imaging within compact proton therapy platforms.

Financing as Catalyst The $65M Series D funding signals strong investor confidence and appetite for scaling; target institutional buyers with financing-friendly options, bundled modernization packages, and phased deployment to reduce CAPEX risk.

Clinical Integration Highlight potential for seamless integration of Marie upright positioning with existing radiotherapy workflows and imaging systems in major cancer centers to improve patient experience and throughput.

Strategic Partnerships Recent collaborations with Orfit and Terapet indicate openness to ecosystem partnerships; approach large cancer centers and equipment providers for co-development, QA integration, and standardized positioning solutions.

Regulatory Readiness With products not yet commercially available pending FDA approval and CE mark, position the company as a research-to-market opportunity for early adopters seeking first-mover advantages and collaborative clinical studies.